#United States #New York #Securities Fraud #Pomerantz LLP #Skye Bioscience

Pomerantz Law Firm Investigates Skye Bioscience

Pomerantz LLP, a well-known law firm specializing in class-action litigation, has announced an investigation concerning Skye Bioscience, Inc. (NASDAQ: SKYE). The focus of this inquiry revolves around potential claims from investors who may have suffered losses due to alleged securities fraud or other illicit business practices involving the company.

On October 6, 2025, Skye Bioscience released information regarding the results of its 26-week Phase 2a CBeyond™ proof-of-concept study for nimacimab, a peripherally-restricted CB1 inhibitor antibody. This release indicated that the nimacimab arm did not meet the primary endpoint of weight loss when compared to a placebo. Moreover, preliminary analysis revealed lower than expected drug exposure, suggesting that a higher dosage might be required for effective results.

Following this announcement, the stock price of Skye experienced a dramatic plunge. Shares dropped by $2.85, marking a 60% decline and closing at $1.90 on the same day. Such a significant drop indicates the potential impact of the study’s findings and raises questions about the company's disclosures and management practices.

Investors who may have been affected by this decline are encouraged to reach out to Pomerantz LLP for guidance. Danielle Peyton can be contacted via email at [email protected] or by phone at 646-581-9980, extension 7980.

Pomerantz LLP is recognized as a leading firm in the fields of securities, antitrust, and corporate class actions. Established over 85 years ago by Abraham L. Pomerantz, often referred to as the father of class-action law, the firm prides itself on its commitment to defend the rights of its clients against corporate misconduct. They have successfully secured numerous multimillion-dollar settlements for class members, advocating for those who have suffered losses due to fraud or violations of fiduciary duty.

As the investigation unfolds, both current and former investors of Skye Bioscience have a critical opportunity to participate in a potential class action lawsuit, formally addressing their grievances against the company and its management. A class action could serve as a collective avenue for addressing the damages and ensuring accountability among corporate executives and directors.

The outcome of Pomerantz's investigation could lead to profound consequences for Skye Bioscience, its leadership, and its investors, highlighting the crucial nature of transparency and integrity in business operations. Investors are advised to remain vigilant and seek proper legal counsel if they suspect any violations of securities law.

In the constantly evolving landscape of biotech companies, where news about clinical trials can significantly impact market value, the vigilance of investors and law firms alike is essential. The Skye Bioscience case serves as a reminder of the volatility and risks inherent in the sector, as well as the growing importance of protecting investor rights through legal mechanisms.

For further updates on the situation or to join the ongoing investigation, interested individuals should keep an eye on the announcements from Pomerantz LLP and consider reaching out to them for more personalized guidance and to understand their options moving forward.